{"Clinical Trial ID": "NCT00036270", "Intervention": ["INTERVENTION 1:", "- Exemestane", "- Exemestane (Aromasin\u00ae) 25 mg QD for 5 years.", "INTERVENTION 2:", "Tamoxifen followed by exemestane", "- tamoxifen 20 mg QD; after 2.5 years to 3 years of tamoxifen, participants were to switch to exemestane 25 mg QD and then to a total of 5 years of endocrine treatment."], "Eligibility": ["Incorporation criteria:", "A histologically/cytologically confirmed breast adenocarcinoma followed by adequate surgical resection and/or radiotherapy, and/or adjuvant chemotherapy, if indicated.", "Stage T1-3 N0-2 MB, Any stage TNM BC for which an adjuvant hormone treatment is being considered.", "- Exclusion criteria:", "Patients who have not been considered to have had primary curative surgical treatment or one of the following:", "Inflammatory breast cancer", "- Histologically positive supraclavic nodes", "Ulceration/infiltration of local skin metastases", "Neoadjuvant chemotherapy", "In-situ ductal carcinoma (CDIS) or lobular carcinoma (LCIS) without invasion", "A negative primary tumour to ER and RA or an unknown status to ER/PR."], "Results": ["Performance measures:", "\u2022 Disease-free survival (DFS): number of reference events (relapsus or death) up to 2.75 years", "Number of events (disease relapses or deaths) up to the time of observation of DFS. DFS is defined as the time of randomization to the earliest documentation of relapse of disease or death of any cause in patients with postmenopausal breast cancer, receptor positive, node negative or node positive for adjuvant treatment with exemestane compared to adjuvant treatment with tamoxifen at 2.75 years of age.", "Time limit: Baseline (month 0) up to 2.75 years", "Results 1:", "Title of the arm/group: Exemestane", "Description of the arm/group: Exemestane (Aromasin) 25 mg QD for 5 years.", "Total number of participants analysed: 4898", "Type of measurement: Number", "Unit of measure: Events (disease or death) 352", "Results 2:", "Title of the arm/group: Tamoxifene followed by Exemestane", "Description of the arm/group: Tamoxifene 20 mg QD; after completing 2.5 years at 3 years of tamoxifen, participants were required to switch to exemestane 25 mg QD and complete a total of 5 years of endocrine treatment.", "Total number of participants analysed: 4868", "Type of measurement: Number", "Unit of measure: Events (disease or death) 388"], "Adverse Events": ["Undesirable Events 1:", "Total: 784/4814 (16.29 per cent)", "Anemia * 5/4814 (0.10%)", "Vitamin B12 deficiency anemia * 1/4814 (0.02%)", "Coagulopathy * 1/4814 (0.02%)", "Febrile neutropenia * 0/4814 (0.00 %)", "Hemorrhagic anaemia * 0/4814 (0.00 %)", "Iron deficiency anaemia * 1/4814 (0.02%)", "- Leucocytosis * 1/4814 (0.02%)", "Leucopenia * 1/4814 (0.02%)", "* 1/4814 (0.02%)", "Neutropenia * 0/4814 (0.00 %)", "Adverse Events 2:", "Total: 831/4852 (17.13 per cent)", "Anemia * 12/4852 (0.25%)", "Vitamin B12 deficiency anaemia * 0/4852 (0.00 %)", "Coagulopathy * 0/4852 (0.00 %)", "Febrile neutropenia * 2/4852 (0.04%)", "Hemorrhagic anaemia * 1/4852 (0.02%)", "Iron deficiency anaemia * 0/4852 (0.00 %)", "- Leucocytosis * 0/4852 (0.00 %)", "Leucopenia * 1/4852 (0.02%)", "* 3/4852 (0.06%)", "Neutropenia * 1/4852 (0.02%)"]}